Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease. J Invest Dermatol. 2020.
Diverse T cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood. 2013.
Epidermal Elafin Expression is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. J Invest Dermatol. 2014.
FLAMSA-based reduced intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an ALWP/EBMT analysis. Biol Blood Marrow Transplant. 2020.